HLX22
Drug timelines are a Plus or Pro feature.
6 regulatory and trial events tracked for HLX22, covering 2024-04-15 to 2026-03-20. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer [Phase 2, Phase 3]